{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [["inhaled corticosteroids", "innate immune markers", "ozone", "sputum neutrophils"]], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "18560537", "DateCompleted": {"Year": "2008", "Month": "12", "Day": "04"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "20"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1289/ehp.10981"], "ArticleDate": [], "Journal": {"ISSN": "0091-6765", "JournalIssue": {"Volume": "116", "Issue": "6", "PubDate": {"Year": "2008", "Month": "Jun"}}, "Title": "Environmental health perspectives", "ISOAbbreviation": "Environ Health Perspect"}, "ArticleTitle": "Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers.", "Pagination": {"StartPage": "799", "EndPage": "805", "MedlinePgn": "799-805"}, "Abstract": {"AbstractText": ["Ozone exposure induces airway neutrophilia and modifies innate immune monocytic cell-surface phenotypes in healthy individuals. High-dose inhaled corticosteroids can reduce O(3)-induced airway inflammation, but their effect on innate immune activation is unknown.", "We used a human O(3) inhalation challenge model to examine the effectiveness of clinically relevant doses of inhaled corticosteroids on airway inflammation and markers of innate immune activation in healthy volunteers.", "Seventeen O(3)-responsive subjects [>10% increase in the percentage of polymorphonuclear leukocytes (PMNs) in sputum, PMNs per milligram vs. baseline sputum] received placebo, or either a single therapeutic dose (0.5 mg) or a high dose (2 mg) of inhaled fluticasone proprionate (FP) 1 hr before a 3-hr O(3) challenge (0.25 ppm) on three separate occasions at least 2 weeks apart. Lung function, exhaled nitric oxide, sputum, and systemic biomarkers were assessed 1-5 hr after the O(3) challenge. To determine the effect of FP on cellular function, we assessed sputum cells from seven subjects by flow cytometry for cell-surface marker activation.", "FP had no effect on O(3)-induced lung function decline. Compared with placebo, 0.5 mg and 2 mg FP reduced O(3)-induced sputum neutrophilia by 18% and 35%, respectively. A similar effect was observed on the airway-specific serum biomarker Clara cell protein 16 (CCP16). Furthermore, FP pretreatment significantly reduced O(3)-induced modification of CD11b, mCD14, CD64, CD16, HLA-DR, and CD86 on sputum monocytes in a dose-dependent manner.", "This study confirmed and extended data demonstrating the protective effect of FP against O(3)-induced airway inflammation and immune cell activation."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina, Chapel Hill, North Carolina 27599-7310, USA. Neil_Alexis@med.unc.edu"}], "Identifier": [], "LastName": "Alexis", "ForeName": "Neil E", "Initials": "NE"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lay", "ForeName": "John C", "Initials": "JC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Haczku", "ForeName": "Angela", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Gong", "ForeName": "Henry", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Linn", "ForeName": "William", "Initials": "W"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hazucha", "ForeName": "Milan J", "Initials": "MJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Harris", "ForeName": "Brad", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Tal-Singer", "ForeName": "Ruth", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Peden", "ForeName": "David B", "Initials": "DB"}], "GrantList": [{"GrantID": "R01 ES012706", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "R01 ES012706-02", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "RC1 ES018505", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "ES012706", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Environ Health Perspect", "NlmUniqueID": "0330411", "ISSNLinking": "0091-6765"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Androstadienes"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "B7-2 Antigen"}, {"RegistryNumber": "0", "NameOfSubstance": "CD11b Antigen"}, {"RegistryNumber": "0", "NameOfSubstance": "HLA-DR Antigens"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, IgG"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "CUT2W21N7U", "NameOfSubstance": "Fluticasone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Androstadienes"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["metabolism"], "DescriptorName": "B7-2 Antigen"}, {"QualifierName": ["metabolism"], "DescriptorName": "CD11b Antigen"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Flow Cytometry"}, {"QualifierName": [], "DescriptorName": "Fluticasone"}, {"QualifierName": ["metabolism"], "DescriptorName": "HLA-DR Antigens"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemically induced", "immunology", "prevention & control"], "DescriptorName": "Inflammation"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Neutrophils"}, {"QualifierName": ["poisoning"], "DescriptorName": "Ozone"}, {"QualifierName": ["metabolism"], "DescriptorName": "Receptors, IgG"}, {"QualifierName": ["cytology", "drug effects", "immunology"], "DescriptorName": "Sputum"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Alexis NE, Becker S, Bromberg PA, Devlin R, Peden DB. Circulating CD11b expression correlates with the neutrophil response and airway mCD14 expression is enhanced following ozone exposure in humans. Clin Immunol. 2004a;111(1):126\u2013131.", "ArticleIdList": ["15093561"]}, {"Citation": "Alexis NE, Eldridge MW, Peden DB. Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol. 2003;112(2):353\u2013361.", "ArticleIdList": ["12897742"]}, {"Citation": "Alexis NE, Eldridge MW, Peden DB. Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol. 2004b;12:353\u2013361.", "ArticleIdList": ["12897742"]}, {"Citation": "Alexis NE, Lay JC, Zeman K, Bennett WE, Peden DB, Soukup JM, et al. Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. J Allergy Clin Immunol. 2006;117:1396\u20131403.", "ArticleIdList": ["16751003"]}, {"Citation": "Alexis NE, Peden DB. Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14. J Allergy Clin Immunol. 2001;108:577\u2013580.", "ArticleIdList": ["11590384"]}, {"Citation": "Alexis N, Soukup J, Ghio A, Becker S. Sputum phagocytes from healthy individuals are functional and activated: a flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. Clin Immunol. 2000a;97:21\u201332.", "ArticleIdList": ["10998314"]}, {"Citation": "Alexis N, Urch B, Tarlo S, Corey P, Pengelly D, O\u2019Byrne P, et al. Cyclooxygenase metabolites play a different role in ozone-induced pulmonary function decline in asthmatics compared to normals. Inhal Toxicol. 2000b;12(12):1205\u20131224.", "ArticleIdList": ["11114789"]}, {"Citation": "American Thoracic Society and European Respiratory Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912\u2013930.", "ArticleIdList": ["15817806"]}, {"Citation": "Bernstein JA, Alexis N, Barnes C, Bernstein IL, Nel A, Peden D, et al. Health effects of air pollution. J Allergy Clin Immunol. 2004;114:1116\u20131123.", "ArticleIdList": ["15536419"]}, {"Citation": "Blomberg A, Mudway IS, Nordenhall C, Hedenstrom H, Kelly FJ, Frew AJ, et al. Ozone-induced lung function decrements do not correlate with early airway inflammatory or antioxidant responses. Eur Respir J. 1999;13(6):1418\u20131428.", "ArticleIdList": ["10445622"]}, {"Citation": "Blomberg A, Mudway I, Svensson M, Hagenbjork-Gustafsson A, Thomasson L, Helleday R, et al. Clara cell protein as a biomarker for ozone-induced lung injury in humans. Eur Respir J. 2003;22:883\u2013888.", "ArticleIdList": ["14680073"]}, {"Citation": "Cao Y, Tao JQ, Bates SR, Beers MF, Haczku A. IL-4 induces production of the lung collectin surfactant protein-D. J Allergy Clin Immunol. 2004;113(3):439\u2013444.", "ArticleIdList": ["15007344"]}, {"Citation": "Enright PL. How to make sure your spirometry tests are of good quality. Respir Care. 2003;48:773\u2013776.", "ArticleIdList": ["12890297"]}, {"Citation": "Gong H, Wong R, Sarma RJ, Linn WS, Sullivan ED, Shamoo DA, et al. Am J Respir Crit Care Med. 1998;158(2):538\u2013546.", "ArticleIdList": ["9700133"]}, {"Citation": "Haczku A. Role and regulation of lung collectins in allergic airway sensitization. Pharmacol Ther. 2006;110(1):14\u201334.", "ArticleIdList": ["16226313"]}, {"Citation": "Hazucha MJ, Madden M, Pape G, Becker S, Devlin R, Koren HS, et al. Effects of cyclo-oxygenase inhibition on ozone-induced respiratory inflammation and lung function changes. Eur J Appl Physiol Occup Physiol. 1996;73(1\u20132):17\u201327.", "ArticleIdList": ["8861665"]}, {"Citation": "Helleday R, Segerstedt B, Forsberg B, Mudway I, Nordberg G, Bernard A, et al. Exploring the time dependence of serum Clara cell protein as a biomarker of pulmonary injury in humans. Chest. 2006;130:672\u2013675.", "ArticleIdList": ["16963661"]}, {"Citation": "Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with \u03b11-antitrypsin deficiency. J Respir Crit Care Med. 1999;160:1968\u20131975.", "ArticleIdList": ["10588615"]}, {"Citation": "Holz O, Jorres FA, Timm P, Mucke M, Richter K, Koschyk S, et al. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med. 1999;159:776\u2013784.", "ArticleIdList": ["10051250"]}, {"Citation": "Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol. 2005;45:498\u2013503.", "ArticleIdList": ["15831772"]}, {"Citation": "Kierstein S, Poulain FR, Cao Y, Grous M, Mathias R, Kierstein G, et al. Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res. 2006;7:85. doi: 10.1186/1465-9921-7-85.", "ArticleIdList": ["10.1186/1465-9921-7-85", "PMC1488844", "16740162"]}, {"Citation": "Koike E, Kobayashi T. Ozone exposure enhances antigen-presenting activity of interstitial lung cells in rats. Toxicology. 2004;196:217\u2013227.", "ArticleIdList": ["15036748"]}, {"Citation": "Lakind JS, Holgate ST, Ownby DR, Mansur AH, Helms PJ, Pyatt D, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers. 2007;12(5):445\u2013467.", "ArticleIdList": ["17701745"]}, {"Citation": "Lay JC, Alexis NE, Kleeberger SR, Roubey RAS, Harris BD, Bromberg PA, et al. Ozone exposure enhances expression of surface markers of innate immunity and antigen presentation on airway monocytes in healthy individuals. J Allergy Clin Immunol. 2007;120(3):719\u2013722.", "ArticleIdList": ["17586033"]}, {"Citation": "Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M, Djukanovi R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9\u201316.", "ArticleIdList": ["10619791"]}, {"Citation": "Maneechotesuwan K, Essilfie-Quaye S, Kharitonov SA, Adcock IM, Barnes PJ. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest. 2007;132(1):98\u2013105.", "ArticleIdList": ["17550933"]}, {"Citation": "McDonnell WF, Stewart PW, Andreoni S, Seal E, Jr, Kehrl HR, Horstman DH, et al. Prediction of ozone-induced FEV1 changes. Effects of concentration, duration, and ventilation. Am J Respir Crit Care Med. 1997;156:715\u2013722.", "ArticleIdList": ["9309984"]}, {"Citation": "Michel O, Murdoch R, Bernard A. Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings. J Allergy Clin Immunol. 2005;115:1143\u20131147.", "ArticleIdList": ["15940126"]}, {"Citation": "Nightingale JA, Rogers DF, Fan CK, Barnes PJ. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med. 2000;161:479\u2013486.", "ArticleIdList": ["10673189"]}, {"Citation": "Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc. 2004;1(2):73\u201376.", "ArticleIdList": ["16113416"]}, {"Citation": "Peden DB. Air pollution in asthma: effect of pollutants on airway inflammation. Ann Allergy Asthma Immunol. 2001;87:12\u201317.", "ArticleIdList": ["11770676"]}, {"Citation": "Scannell C, Chen L, Aris RM, Tager I, Christian D, Ferrando R, et al. Greater ozone-induced inflammatory responses in subjects with asthma. Am J Respir Crit Care Med. 1996;154(1):24\u201329.", "ArticleIdList": ["8680687"]}, {"Citation": "Singh R, Tal-Singer R, Faiferman I, Lasenby S, Henderson A, Wessels D, et al. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomised, double blind, placebo controlled, crossover study in healthy subjects. Br J Clin Pharm. 2006;61(4):398\u2013404.", "ArticleIdList": ["PMC1885034", "16542200"]}, {"Citation": "Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax. 1998;53:58\u201362.", "ArticleIdList": ["PMC1758695", "9577524"]}, {"Citation": "Vagaggini B, Taccola M, Conti I, Carnevali S, Cianchetti S, Bartoli ML, et al. Budesonide reduces neutrophilic but not functional airway response to ozone in mild asthmatics. Am J Respir Crit Care Med. 2001;164:2172\u20132176.", "ArticleIdList": ["11751182"]}, {"Citation": "Wenzel S. Severe/fatal asthma. Chest. 2003;123:405S\u2013410S.", "ArticleIdList": ["12629003"]}, {"Citation": "Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001\u20131008.", "ArticleIdList": ["10471631"]}]}], "History": [{"Year": "2007", "Month": "10", "Day": "15"}, {"Year": "2008", "Month": "2", "Day": "27"}, {"Year": "2008", "Month": "6", "Day": "19", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "12", "Day": "17", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "6", "Day": "19", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "6", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["18560537", "PMC2430237", "10.1289/ehp.10981"]}}], "PubmedBookArticle": []}